Shares of BriaCell Therapeutics Corp. (OTCMKTS:BCTXF – Get Free Report) were down 2.9% on Thursday . The company traded as low as $0.68 and last traded at $0.70. Approximately 59,940 shares were traded during mid-day trading, an increase of 3,124% from the average daily volume of 1,859 shares. The stock had previously closed at $0.72.
BriaCell Therapeutics Price Performance
The firm has a market capitalization of $562,788.00, a price-to-earnings ratio of -0.18 and a beta of 1.09. The business has a fifty day moving average price of $0.79 and a two-hundred day moving average price of $1.74.
BriaCell Therapeutics Company Profile
BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT.
Featured Articles
- Five stocks we like better than BriaCell Therapeutics
- The 3 Best Blue-Chip Stocks to Buy Now
- Is Merck Stock Undervalued After Its Colossal Earnings Growth?
- How to Effectively Use the MarketBeat Ratings Screener
- Top 5 ETFs for Every Investor: From Semiconductors to Defense
- What is the S&P/TSX Index?
- Blade Air Mobility: This Under-the-Radar Stock Could Double Soon
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
